You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRibostamycin
Accession NumberDB03615  (EXPT02786)
TypeSmall Molecule
GroupsApproved
DescriptionA broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus. Ribostamycin, along with other aminoglycosides with the DOS (2-deoxystreptamine) subunit, is an important broad-spectrum antibiotic with important use against human immunodeficiency virus and is considered a critically important antimicrobial by the World Health Organization.
Structure
Thumb
Synonyms
5-Amino-2-Aminomethyl-6-[4,6-Diamino-2-(3,4-Dihydroxy-5-Hydroxymethyl-Tetrahydro-Furan-2-Yloxy)-3-Hydroxy-Cyclohexyloxy]-Tetrahydro-Pyran-3,4-Diol
Ribastamin
RIO
Vistamycin
Xylostacin
Xylostasin
External Identifiers
  • Antibiotic SF 733
  • SF-733
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII2Q5JOU7T53
CAS number25546-65-0
WeightAverage: 454.4727
Monoisotopic: 454.227493328
Chemical FormulaC17H34N4O10
InChI KeyInChIKey=NSKGQURZWSPSBC-NLZFXWNVSA-N
InChI
InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13+,14-,15-,16+,17-/m0/s1
IUPAC Name
(2S,3R,4S,5S,6R)-5-amino-2-(aminomethyl)-6-{[(1S,2S,3R,4S,6R)-4,6-diamino-2-{[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol
SMILES
NC[C@@H]1O[[email protected]](O[[email protected]]2[[email protected]](N)C[[email protected]](N)[C@@H](O)[C@@H]2O[C@@H]2O[C@@H](CO)[[email protected]](O)[[email protected]]2O)[C@@H](N)[[email protected]](O)[[email protected]]1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amino sugars. These are sugars having one alcoholic hydroxy group replaced by an amino group; systematically known as x-amino-x-deoxymonosaccharides. These compounds do not include Glycosylamines.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassAminosaccharides
Direct ParentAmino sugars
Alternative Parents
Substituents
  • 4,5-disubstituted 2-deoxystreptamine
  • Aminoglycoside core
  • 2-deoxystreptamine aminoglycoside
  • Glucosamine
  • Amino sugar
  • O-glycosyl compound
  • Glycosyl compound
  • Cyclohexylamine
  • Cyclohexanol
  • Oxane
  • Monosaccharide
  • Oxolane
  • Cyclic alcohol
  • Secondary alcohol
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Primary alcohol
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionAminoglycosides work by binding to the bacterial 30S ribosomal subunit (some work by binding to the 50S subunit), inhibiting the translocation of the peptidyl-tRNA from the A-site to the P-site and also causing misreading of mRNA, leaving the bacterium unable to synthesize proteins vital to its growth. However, their exact mechanism of action is not fully known.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8617
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7502
P-glycoprotein substrateNon-substrate0.5164
P-glycoprotein inhibitor INon-inhibitor0.8023
P-glycoprotein inhibitor IINon-inhibitor0.8764
Renal organic cation transporterNon-inhibitor0.7886
CYP450 2C9 substrateNon-substrate0.8231
CYP450 2D6 substrateNon-substrate0.8041
CYP450 3A4 substrateNon-substrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9157
CYP450 2C9 inhibitorNon-inhibitor0.9147
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9034
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8446
Ames testNon AMES toxic0.6934
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.8587
Rat acute toxicity1.4850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9728
hERG inhibition (predictor II)Non-inhibitor0.81
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point193.5 °CPhysProp
pKa7.7MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility88.7 mg/mLALOGPS
logP-2.9ALOGPS
logP-6.4ChemAxon
logS-0.71ALOGPS
pKa (Strongest Acidic)12.19ChemAxon
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge4ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count10ChemAxon
Polar Surface Area262.38 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity100.17 m3·mol-1ChemAxon
Polarizability44.43 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Eiichi Akita, Tsutomu Tsuchiya, Shinichi Kondo, Shuntaro Yasuda, Sumio Umezawa, Hamao Umezawa, “1-N-((S)-.alpha.-substituted-.omega.-aminoacyl)-neamine or -ribostamycin and the production thereof.” U.S. Patent US4008218, issued February, 1974.

US4008218
General ReferencesNot Available
External Links
ATC CodesJ01GB10
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AceclofenacAceclofenac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Ribostamycin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
AdapaleneAdapalene may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Alendronic acidRibostamycin may increase the hypocalcemic activities of Alendronic acid.
AmdinocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Amdinocillin.
AmoxicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Amoxicillin.
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Ribostamycin.
AmpicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Ampicillin.
AntipyrineAntipyrine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
ApremilastApremilast may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
AzapropazoneAzapropazone may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
AzelastineAzelastine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
AzlocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Azlocillin.
BalsalazideBalsalazide may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
BenoxaprofenBenoxaprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Benzathine benzylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Benzathine benzylpenicillin.
BenzylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicillin.
Benzylpenicillin PotassiumThe serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicillin Potassium.
Botulinum Toxin Type ARibostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.
Botulinum Toxin Type BRibostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.
BromfenacBromfenac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ribostamycin.
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Ribostamycin.
CarbenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Carbenicillin.
CarboplatinRibostamycin may increase the ototoxic activities of Carboplatin.
CarprofenCarprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
CastanospermineCastanospermine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
CelecoxibCelecoxib may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
ChloroquineChloroquine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
CisplatinCisplatin may increase the nephrotoxic activities of Ribostamycin.
ClodronateRibostamycin may increase the hypocalcemic activities of Clodronate.
ClonixinClonixin may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
CloxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Cloxacillin.
ColistimethateRibostamycin may increase the nephrotoxic activities of Colistimethate.
CyclacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Cyclacillin.
CyclosporineRibostamycin may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneD-Limonene may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Ribostamycin.
DiclofenacDiclofenac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
DicloxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Dicloxacillin.
DiflunisalDiflunisal may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Ribostamycin.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Ribostamycin.
DroxicamDroxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
EpirizoleEpirizole may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ribostamycin.
EtanerceptEtanercept may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Etidronic acidRibostamycin may increase the hypocalcemic activities of Etidronic acid.
EtodolacEtodolac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
EtofenamateEtofenamate may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
EtoricoxibEtoricoxib may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Evening primrose oilEvening primrose oil may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
exisulindexisulind may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
FenbufenFenbufen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
FenoprofenFenoprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
FloctafenineFloctafenine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
FlucloxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Flucloxacillin.
FlunixinFlunixin may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
FlurbiprofenFlurbiprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
FoscarnetFoscarnet may increase the nephrotoxic activities of Ribostamycin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Ribostamycin.
HMPL-004HMPL-004 may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateRibostamycin may increase the hypocalcemic activities of Ibandronate.
IbuprofenIbuprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
IbuproxamIbuproxam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
IcatibantIcatibant may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
IndomethacinIndomethacin may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
IndoprofenIndoprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
IsoxicamIsoxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneKebuzone may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
KetoprofenKetoprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
KetorolacKetorolac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
LeflunomideLeflunomide may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
LornoxicamLornoxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
LoxoprofenLoxoprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
LumiracoxibLumiracoxib may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
MannitolMannitol may increase the nephrotoxic activities of Ribostamycin.
MasoprocolMasoprocol may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
MecamylamineRibostamycin may increase the neuromuscular blocking activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Mefenamic acidMefenamic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
MeloxicamMeloxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
MesalazineMesalazine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
MetamizoleMetamizole may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
MeticillinThe serum concentration of Ribostamycin can be decreased when it is combined with Meticillin.
MezlocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Mezlocillin.
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
NabumetoneNabumetone may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
NafcillinThe serum concentration of Ribostamycin can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
NaproxenNaproxen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
NCX 4016NCX 4016 may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacNepafenac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidNiflumic Acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
NimesulideNimesulide may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
OlopatadineOlopatadine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
OlsalazineOlsalazine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
OrgoteinOrgotein may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Ribostamycin.
OxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Oxacillin.
OxaprozinOxaprozin may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
PamidronateRibostamycin may increase the hypocalcemic activities of Pamidronate.
ParecoxibParecoxib may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
PhenoxymethylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Phenoxymethylpenicillin.
PhenylbutazonePhenylbutazone may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ribostamycin.
PimecrolimusPimecrolimus may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
PiperacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Piperacillin.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Ribostamycin.
PirfenidonePirfenidone may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
PiroxicamPiroxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
PivampicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Pivampicillin.
PivmecillinamThe serum concentration of Ribostamycin can be decreased when it is combined with Pivmecillinam.
Procaine benzylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Procaine benzylpenicillin.
PropacetamolPropacetamol may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
PTC299PTC299 may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
ResveratrolResveratrol may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateRibostamycin may increase the hypocalcemic activities of Risedronate.
RofecoxibRofecoxib may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
SalicylamideSalicylamide may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Salicylic acidSalicylic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
SalsalateSalsalate may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
SeratrodastSeratrodast may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
SRT501SRT501 may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
SulbactamThe serum concentration of Ribostamycin can be decreased when it is combined with Sulbactam.
SulfasalazineSulfasalazine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
SulindacSulindac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
SuprofenSuprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Technetium Tc-99m MedronateRibostamycin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.
TenofovirThe serum concentration of Ribostamycin can be increased when it is combined with Tenofovir.
TenoxicamTenoxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
TepoxalinTepoxalin may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
TeriflunomideTeriflunomide may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
TicarcillinThe serum concentration of Ribostamycin can be decreased when it is combined with Ticarcillin.
TiludronateRibostamycin may increase the hypocalcemic activities of Tiludronate.
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
TolmetinTolmetin may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Ribostamycin.
TranilastTranilast may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
ValdecoxibValdecoxib may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
VancomycinVancomycin may increase the nephrotoxic activities of Ribostamycin.
ZaltoprofenZaltoprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
ZileutonZileuton may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Zoledronic acidRibostamycin may increase the hypocalcemic activities of Zoledronic acid.
ZomepiracZomepirac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This multifunctional protein catalyzes the formation, breakage and rearrangement of disulfide bonds. At the cell surface, seems to act as a reductase that cleaves disulfide bonds of proteins attached to the cell. May therefore cause structural modifications of exofacial proteins. Inside the cell, seems to form/rearrange disulfide bonds of nascent proteins. At high concentrations, functions as a...
Gene Name:
P4HB
Uniprot ID:
P07237
Molecular Weight:
57115.795 Da
References
  1. Horibe T, Nagai H, Sakakibara K, Hagiwara Y, Kikuchi M: Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289(5):967-72. [PubMed:11741285 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
unknown
General Function:
Trna binding
Specific Function:
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Located at the interface of the 30S and 50S subunits, it traverses the body of the 30S subunit contacting proteins on the other side and probably holding the rRNA structure together. The combined cluste...
Gene Name:
rpsL
Uniprot ID:
P0A7S3
Molecular Weight:
13736.995 Da
Kind
Protein
Organism
Salmonella enteritidis
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Catalyzes the transfer of an acetyl group from acetyl-CoA to the 6'-amino group of aminoglycoside molecules conferring resistance to antibiotics containing the purpurosamine ring including amikacin, tobramycin, dibekacin and ribostamycin. Able to acetylate eukaryotic histone proteins.
Gene Name:
Not Available
Uniprot ID:
Q9R381
Molecular Weight:
16361.42 Da
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
unknown
General Function:
Involved in N-acetyltransferase activity
Specific Function:
Catalyzes the coenzyme A-dependent acetylation of the 2' hydroxyl or amino group of a broad spectrum of aminoglycosides. It confers resistance to aminoglycosides
Gene Name:
aac
Uniprot ID:
P0A5N0
Molecular Weight:
20038.0 Da

Enzymes

Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
unknown
General Function:
Involved in N-acetyltransferase activity
Specific Function:
Catalyzes the coenzyme A-dependent acetylation of the 2' hydroxyl or amino group of a broad spectrum of aminoglycosides. It confers resistance to aminoglycosides
Gene Name:
aac
Uniprot ID:
P0A5N0
Molecular Weight:
20038.0 Da
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23